Amgen Does Not Expect Big Enbrel Price Impact From US Humira Biosimilar Launches
Q3 Revenue Down 1% But Beat Analyst Consensus
Executive Summary
Amgen will be first to launch a Humira biosimilar in the US with its Amgevita, but it and other adalimumab copies may add pressure to the company’s already declining top-seller Enbrel.
You may also be interested in...
As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth
With previously leading Amgen biosimilars such as Mvasi (bevacizumab) and Kanjinti (trastuzumab) seeing their sales decline, the firm is turning its attention to the next wave of biosimilars that will drive future growth.
Lack Of Interchangeability No Barrier For Amjevita, Says Amgen Executive
While Amgen’s Amjevita (adalimumab-atto) has yet to secure an interchangeability designation, company executives appear confident this will have little impact on their Humira biosimilar’s competitiveness overall.
Humira One Year Out: The Largest LOE Event In US Pharma History
Ahead of the first biosimilar Humira product set to launch in 365 days, Generics Bulletin provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.